Buscar
Mostrando ítems 11-20 de 822
Impact of automatic replacement in stable patients
Dr. Murali Gopal , director of Global Medical Healthcare Solutions at Abbvie talks about famacocinéticas structures, pharmacodynamic and TNF inhibitors.
Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus
(Oxford Univ Press Inc, 2018)
Background. Aspergillus flavus is one of the most common agents of invasive aspergillosis and is associated with high mortality. The orotomides are a new class of antifungal agents with a novel mechanism of action. An ...
Models for evaluating the pharmacokinetics and pharmacodynamics for β-blockers
(Informa Healthcare, 2014-04)
Introduction: β-blocker therapy plays an important role in the treatment of various diseases, including hypertension, myocardial infarction and heart failure. Although all β-blockers shared their ability to competitively ...
Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C
(Taylor & Francis, 2018-06)
Introduction: Many reports have evaluated the clinical efficacy and safety of the fixed-dose all-oral combination of daclatasvir, asunaprevir, and beclabuvir (DCV-TRIO), which was approved in Japan in December 2016 for the ...
Applicability of microdialysis as a technique for pharmacokinetic- pharmacodynamic (PK-PD) modeling of antihypertensive beta-blockers
(Elsevier, 2005-09)
Introduction: The aim of the present work was to examine microdialysis as a technique for the study of pharmacokinetic-pharmacodynamic modeling of antihypertensive drugs. For this purpose, we studied the antihypertensive ...